Sanofi, the maker of the UK’s number one selling[1] Irritable Bowel Syndrome (IBS) brand Buscopan, is launching new multi-symptom IBS treatment, BuscoMint Peppermint Oil 0.2ml gastro-resistant capsule, soft. BuscoMint provides an effective and scientifically proven[2] way to treat a variety of abdominal discomfort symptoms, such as abdominal pain, cramps and bloating, especially in those who suffer from IBS.
As the latest addition to the Busco range following the launch of the food supplement Buscobiota earlier this year, BuscoMint is the range’s first ever multi-symptom treatment for IBS. It works by targeting the source of pain using gastro-resistant soft gel capsules that release in the bowel. Each capsule contains 0.2ml of 100% natural peppermint oil (the equivalent of around 67 cups of peppermint tea) to provide effective 3 in 1 relief from abdominal pain, cramps and bloating.
To mark the exciting arrival of BuscoMint, Sanofi is introducing its first ever digital brand partnership with digestive health app Cara Care alongside the launch of the new antispasmodic BuscoMint Peppermint Oil 0.2ml gastro-resistant capsule, soft.
Cara Care is a digital platform that helps people with gastrointestinal issues manage their gut health through nutritional advice and various holistic techniques. The app, which is free to download, also offers a range of premium paid features including a personalised 12 weeks guided IBS programme.
The premium programme offered by Cara Care costs £89 a month and includes unlimited text chat support with a dietitian, a 12-week diet plan, food lists, and personalised analysis of the symptom and food data tracked in the app. Additionally, the program offers audio-guided hypnosis and mindfulness modules to help combat stress.
To celebrate the partnership, BuscoMint and Cara Care have teamed up to offer users one week of free access to the premium guided IBS programme. Users simply have to visit the Buscopan website and complete a short survey on the Cara Care page to be eligible.
Silvina Vilas, Marketing Director of UK and Ireland Sanofi Consumer Health Care, comments: “The launch of BuscoMint to our Busco range and the collaboration with Cara Care represents a significant milestone in our abdominal pain offering. Through the partnership, we can now offer consumers a holistic approach to managing IBS. The Cara Care app can help to track symptoms and aid condition understanding and BuscoMint can be used in combination with a healthy lifestyle to treat symptoms. With 20% of the UK population suffering from IBS[3], we hope this ‘Track’ and ‘Treat’ proposition will enable consumers to better manage their symptoms so they can live healthier and fuller lives.”
André Sommer, Medical Doctor and Co-Founder at Cara Care, adds: “We are excited to combine several guidelines recommended solutions for IBS into one joint offering. A holistic approach to IBS includes several components: self-awareness with tracking, dietary and/or mental health behaviour change, and physical treatment. World gastroenterology organisation global guidelines recommend peppermint oil as first line therapy for overall IBS symptoms4.Sanofi’s experience in the IBS space with their Busco family makes BuscoMint our preferred partner to bring a combined solution to millions of people in the UK.”
For more information about the BuscoMint and Cara Care collaboration, please visit: Buscopan.co.uk/products/buscomint. BuscoMint is priced £6.99 for 24 soft gel capsules and is available from Boots, Superdrug, Asda, Tesco, Morrisons and Amazon.
Buscopan IBS Relief is for medically confirmed IBS. Buscopan IBS Relief contains hyoscine butylbromide. Always read the label.
Buscomint® Peppermint oil 0.2ml gastro-resistant soft capsules. For the symptomatic relief of abdominal pain, abdominal cramps and flatulence in IBS. Always read the label.
References
[1] Based on Sales data Nielsen UK 09/2020
[2] https://cks.nice.org.uk/topics/irritable-bowel-syndrome/prescribing-information/antispasmodic-drugs/
[3] ISM Buscopan Quant potential study Nov 2015. Kantar IMS mkt penetration Dec 2018
[4] World Gastroenterology Organisation Global Guidelines IBS
